Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024
February 01, 2024 at 02:33 am IST
Share
Paragon 28, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects net revenue to be $249 million to $259 million, representing 15.1% and 19.7% reported growth compared to 2023.
Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Companyâs suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patientâs anatomical and surgical requirements.
PARAGON 28, INC. 
